Amgen's experimental drug trebananib, or AMG 386, in combination with paclitaxel, achieved the primary goal of a late-stage study by extending progression-free survival in patients with ovarian cancer. Patients who took trebananib survived 7.2 months without their disease worsening compared with 5.4 months for those in the control group.

Related Summaries